RxDoctor Payments Data

William Knight, MD

Family Medicine · Savannah, GANPI 1356621890

Payments from drug & device makers

$12,576in general payments, 2019–2025

Across 745 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Novartis$1K
  • AbbVie$1K
  • GSK$833
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$12,47699%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,576 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$255,726
Medicare patients
518
Services billed
12,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide168$262,002
JardianceEmpagliflozin115$145,144
RybelsusSemaglutide70$133,319
EliquisApixaban133$120,677
TrulicityDulaglutide79$120,057
FarxigaDapagliflozin Propanediol97$119,824
MounjaroTirzepatide66$104,018
LinzessLinaclotide80$88,520
JanuviaSitagliptin Phosphate78$75,387
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$67,897
Tresiba Flextouch U-100Insulin Degludec62$53,672
XareltoRivaroxaban62$42,518
KerendiaFinerenone30$39,282
MyrbetriqMirabegron37$38,680
Repatha SureclickEvolocumab25$29,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,136$395,321238 claims
Lilly USA, LLCTrulicity, Mounjaro$789$224,074145 claims
Boehringer IngelheimJardiance$360$145,144115 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,392$143,658135 claims
PfizerEliquis$520$120,677133 claims
AbbVieLinzess, Restasis, Synthroid$1,015$111,766167 claims
MerckJanuvia, Janumet Xr$418$92,65695 claims
GSKTrelegy Ellipta, Breo Ellipta$833$85,49388 claims
Johnson & JohnsonXarelto$693$42,51862 claims
BayerKerendia$355$39,28230 claims
Astellas Pharma US IncMyrbetriq$119$38,68037 claims
Avanir Pharmaceuticals, Inc.Nuedexta$11$18,58012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →